| ADTX 0.0127 -2.31% | SOXS 4.72 -5.03% | SPCX 160.95 19.22% | DFNS 0.233 -9.20% | BITO 8.65 0.12% | RUBI 0.4676 -24.62% | TZA 4.16 -2.58% | CAST 1.55 140.68% | AAL 14.98 2.25% | INTC 124.57 6.51% | SPCE 3.91 -31.76% | SHFS 0.276 16.46% | SRXH 0.148 17.65% | NOK 14.795 5.00% | NVDA 205.19 0.16% | BYAH 1.47 40.00% | SPDN 8.81 -0.45% | TQQQ 77.52 1.99% | TSLL 13.59 3.58% | PAVS 0.208 -28.28% | CPOP 0.195 -81.43% | SMCI 30.46 -4.72% | CUPR 3.97 64.73% | VSME 1.69 52.25% | YYGH 0.119 -3.25% | SQQQ 40.04 -1.93% | RKLB 102.39 -10.79% | TSLA 406.43 1.82% | NVD 5.02 -0.40% | WOK 0.0753 -17.70% | SPY 741.75 0.54% | ASTS 82.41 -15.53% | KEEL 5.59 1.27% | ONDS 9.33 -5.09% | SPYM 87.06 0.25% | AMZN 238.55 -1.23% | XLF 53.34 1.37% | SATS 114.08 -10.97% | QQQ 721.34 0.59% | SOFI 16.58 -0.54% | PLUG 2.76 -2.47% | SOXL 234.68 4.77% | GRAB 3.3 -1.49% | DRIP 4.74 -2.47% | AMC 2.34 2.63% | IREN 59.77 5.40% | HKIT 0.5025 -10.11% | RKLZ 3.01 21.37% | RZLV 2.68 5.93% | MARA 14.08 3.45%

cbdMD, Inc. (AMEX: YCBD) Q2 Earnings: Revenue Growth Amidst EPS Miss in the Cannabinoid Market

cbdMD, Inc. (AMEX: YCBD) is a prominent wellness company that operates several brands in the rapidly expanding cannabinoid industry. These include cbdMD, Bluebird Botanicals, Paw CBD, and the THC beverage brand Oasis. On May 14, 2026, the company reported its second-quarter earnings, providing key insights into its financial performance and market position, which showed a mix of positive and negative results compared to analyst expectations.

The cannabinoid stock posted revenue of $5.64 million, impressively surpassing the analyst consensus estimate of $5.29 million. This represents a significant 19% year-over-year and 12% sequential revenue growth. This increase was primarily driven by cbdMD's core business operations and the recent strategic acquisition of Bluebird Botanicals, as highlighted by PR Newswire, underscoring the company's growth initiatives in the competitive wellness market.

Despite the strong revenue performance, YCBD announced an earnings per share of -$0.08, which unfortunately missed the analyst estimate of -$0.05. This unprofitability is also reflected in its negative earnings yield of -103.83% and a trailing price-to-earnings (P/E) ratio of -0.01. A negative P/E ratio indicates that a company has negative earnings, a crucial metric for investors evaluating profitability.

From a valuation perspective, YCBD has a price-to-sales (P/S) ratio of 0.0015. The P/S ratio compares a company's stock price to its revenues, and a low ratio can sometimes suggest that a stock is undervalued relative to its sales, offering potential investment opportunities. The company's enterprise value-to-operating cash flow is 1.45, another important valuation metric for financial analysis.

However, the company shows strong financial stability, a positive sign for long-term investors. YCBD maintains a low debt-to-equity ratio of 0.044, demonstrating that it does not rely heavily on debt financing. Furthermore, its current ratio of 2.82 suggests a robust capacity to cover its short-term obligations, as it holds $2.82 in assets for every $1 in liabilities due soon, indicating excellent liquidity management.

Published on: May 15, 2026